Literature DB >> 11123382

Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans.

R Pacifici1, P Zuccaro, C Hernandez López, S Pichini, S Di Carlo, M Farré, P N Roset, J Ortuño, J Segura, R L Torre.   

Abstract

Cell-mediated immune response and release of cytokines after the administration of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") alone and in combination with ethanol were assessed in a double blind, randomized, crossover, controlled clinical trial. Six healthy male recreational users of MDMA participated in four different experimental sessions, with a washout interval between sessions of 1 week, in which single oral doses of MDMA (100 mg), ethanol (0.8 g/kg), the combination of both drugs, and placebo were tested. Acute MDMA administration produced a time-dependent immune dysfunction in association with serum concentrations of the drug as well as cortisol stimulation kinetics. Although total leukocyte count remained unchanged, there was a decrease in the CD4 T/CD8 T-cell ratio due to a decrease in both the percentage and absolute number of CD4 T-helper cells and simultaneous increase in natural killer (NK) cells. Ethanol consumption produced a decrease in T-helper cells and B lymphocytes. The combination of MDMA and ethanol caused the highest suppressive effect on CD4 T cells and increasing effect in NK cells. Drugs treatment produced a high increase of immunosuppressive cytokines (transforming growth factor-beta and interleukin-10) and a switch from Th1-type cytokines (interleukin-2 and interferon-gamma) to Th2-type cytokines (interleukin-4 and interleukin-10). Disregulation in the production of pro- and anti-inflammatory cytokines with an unbalance toward anti-inflammatory response was also observed. The immune function shows a trend toward baseline levels at 24 h after MDMA kinetics. This transient defect in immunological homeostasis, if temporarily repeated, might alter the immune response with a risk for the general health status.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123382

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  "Ecstasy" induced immunosuppression and herpes zoster ophthalmicus.

Authors:  O M Zwick; D H Fischer; J C Flanagan
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

2.  3,4-Methylenedioxymethamphetamine (MDMA) alters acute gammaherpesvirus burden and limits interleukin 27 responses in a mouse model of viral infection.

Authors:  Daniel A Nelson; Sam J Singh; Amy B Young; Melanie D Tolbert; Kenneth L Bost
Journal:  Drug Alcohol Depend       Date:  2011-01-26       Impact factor: 4.492

3.  3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity.

Authors:  Michael T Williams; Tori L Schaefer; Lisa A Ehrman; Jessica A Able; Gary A Gudelsky; Renu Sah; Charles V Vorhees
Journal:  Brain Res       Date:  2005-03-28       Impact factor: 3.252

4.  Serotonin modulates the cytokine network in the lung: involvement of prostaglandin E2.

Authors:  G Ménard; V Turmel; E Y Bissonnette
Journal:  Clin Exp Immunol       Date:  2007-09-05       Impact factor: 4.330

5.  Drug interaction between ethanol and 3,4-methylenedioxymethamphetamine ("ecstasy").

Authors:  Vijay V Upreti; Natalie D Eddington; Kwan-Hoon Moon; Byoung-Joon Song; Insong J Lee
Journal:  Toxicol Lett       Date:  2009-04-05       Impact factor: 4.372

6.  Ecstasy (3,4-methylenedioxymethamphetamine) limits murine gammaherpesvirus-68 induced monokine expression.

Authors:  Daniel A Nelson; Jamie L Nirmaier; Sam J Singh; Melanie D Tolbert; Kenneth L Bost
Journal:  Brain Behav Immun       Date:  2008-02-15       Impact factor: 7.217

Review 7.  Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system.

Authors:  Thomas J Connor
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

8.  Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

9.  Recreational amphetamine use and risk of HIV-related non-Hodgkin lymphoma.

Authors:  Chun Chao; Lisa P Jacobson; Donald Tashkin; Otoniel Martínez-Maza; Michael D Roth; Joseph B Margolick; Joan S Chmiel; Marcy N Holloway; Zuo-Feng Zhang; Roger Detels
Journal:  Cancer Causes Control       Date:  2008-11-15       Impact factor: 2.506

10.  Expression of neuronal trace amine-associated receptor (Taar) mRNAs in leukocytes.

Authors:  Daniel A Nelson; Melanie D Tolbert; Sam J Singh; Kenneth L Bost
Journal:  J Neuroimmunol       Date:  2007-09-27       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.